Tegavivint for the Treatment of Relapsed or Refractory Leukemia
Phase I Study of Tegavivint (BC-2059) in Patients With Relapsed and Refractory Leukemias
Sponsor: M.D. Anderson Cancer Center
Listed as NCT04874480, this PHASE1 trial focuses on Recurrent Leukemia and Refractory Leukemia and remains ongoing. Sponsored by M.D. Anderson Cancer Center, it has been updated 14 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Mar 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .